Beam Therapeutics Inc. (BEAM) - Dilution Analysis

10-Q filing | 103.3M shares outstanding

10-Q filing | 102.6M shares outstanding

10-Q filing | 102.0M shares outstanding

8-K filing: Beam Therapeutics Inc. issued 403,128 shares of common stock as an upfront payment for the acquisition of an early-stage life sciences company on July 1, 2025, and may issue up to 5,232,216 additional shares upon achievement of certain milestones.

10-Q filing | 100.6M shares outstanding

10-K filing | 82.3M shares outstanding

10-Q filing | 82.4M shares outstanding

10-Q filing | 82.3M shares outstanding

10-Q filing | 81.7M shares outstanding

10-K filing | 77.2M shares outstanding

10-Q filing | 79.0M shares outstanding

10-Q filing | 76.3M shares outstanding

10-Q filing | 72.3M shares outstanding

10-K filing | 70.0M shares outstanding

10-Q filing | 70.3M shares outstanding

8-K filing: Beam Therapeutics Inc. entered into a license and research collaboration agreement with Orbital Therapeutics, Inc., pursuant to which Orbital issued to the Company 75 million shares of its common stock.

10-Q filing | 70.2M shares outstanding

10-Q filing | 68.7M shares outstanding

10-K filing | 64.2M shares outstanding

10-Q filing | 66.4M shares outstanding

10-Q filing | 62.2M shares outstanding

10-Q filing | 62.6M shares outstanding

10-K filing | 62.4M shares outstanding

8-K filing: Beam Therapeutics Inc. entered into a Securities Purchase Agreement to sell and issue 2,795,700 shares of common stock at $93.00 per share in a private placement, for aggregate gross proceeds of approximately $260.0 million. ($260.0M proceeds)

10-Q filing | 58.0M shares outstanding

S-1 filing: An S-1 filing was submitted on 2020-09-28 for a common stock offering. The company intends to use the net proceeds from this offering for continued advancement of our platform technology, for continued research and development of our current portfolio of base editing programs and for other potential programs, for conducting preclinical studies, including potential preclinical proof-of-concept of our three delivery modalities, for IND-enabling studies and the potential initiation of clinical studies for certain of our current programs, for building-out our in-house manufacturing facility, and for general corporate purposes.

10-Q filing | 51.7M shares outstanding

10-Q filing | 51.5M shares outstanding

S-1/A filing: This S-1/A filing relates to a common stock offering with an option for underwriters to purchase additional shares. The company estimates net proceeds of approximately $134.3 million, assuming an initial public offering price of $16.00 per share.

S-1/A filing: This S-1/A filing from 2020-01-31 discusses an initial public offering of common stock with an estimated net proceeds of $89.8 million, assuming an IPO price of $16.00 per share. It also mentions the underwriters having an option to purchase additional shares and the registration rights of certain stockholders.

S-1/A filing: This S-1/A filing relates to an initial public offering of common stock with an option for underwriters to purchase additional shares.

S-1/A filing: This S-1/A filing from 2020-01-17 discusses an option for underwriters to purchase additional common stock, registration rights for existing shareholders, and the authorization of preferred stock issuance.